Audited Financial Results for the Fourth Quarter (Q4) and Financial Year ended 31 March 2026.
MPSLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts more than Nifty Microcap 250 and 7.6 pts more than its Printing & Publication peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
MPS Limited reported standalone total income of INR 38,125 lakhs for FY 2025-26, up 14.4% from INR 33,336 lakhs in the previous year. Profit after tax stood at INR 12,726 lakhs versus INR 11,000 lakhs in FY 2024-25, representing approximately 16% PAT growth. The Board did not recommend a final dividend for FY 2025-26, citing deployment of cash towards the acquisition of Unbound Medicine, Inc. completed on 9 February 2026. The company also appointed KPMG as new Internal Auditors from FY 2026-27 and re-appointed Walker Chandiok & Co LLP as Statutory Auditors. The Auditor issued an unmodified (clean) opinion on both standalone and consolidated financial results with no going concern or emphasis of matter issues.
The 14% revenue and 16% PAT growth reflect solid operational performance, though below high-growth thresholds. No dividend payout signals management prioritising acquisitions for growth over shareholder returns in the near term. Clean audit opinion is positive for investor confidence.